MULPLETA Drug Patent Profile
✉ Email this page to a colleague
When do Mulpleta patents expire, and when can generic versions of Mulpleta launch?
Mulpleta is a drug marketed by Vancocin Italia and is included in one NDA. There are four patents protecting this drug.
This drug has fifty-six patent family members in twenty countries.
The generic ingredient in MULPLETA is lusutrombopag. One supplier is listed for this compound. Additional details are available on the lusutrombopag profile page.
DrugPatentWatch® Generic Entry Outlook for Mulpleta
Mulpleta was eligible for patent challenges on July 31, 2022.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 29, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for MULPLETA
International Patents: | 56 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 41 |
Patent Applications: | 24 |
Drug Prices: | Drug price information for MULPLETA |
What excipients (inactive ingredients) are in MULPLETA? | MULPLETA excipients list |
DailyMed Link: | MULPLETA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MULPLETA
Generic Entry Date for MULPLETA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for MULPLETA
US Patents and Regulatory Information for MULPLETA
MULPLETA is protected by four US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MULPLETA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting MULPLETA
Compounds exhibiting thrombopoietin receptor agonism
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE
Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Preparation for improving solubility of poorly soluble drug
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vancocin Italia | MULPLETA | lusutrombopag | TABLET;ORAL | 210923-001 | Jul 31, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Vancocin Italia | MULPLETA | lusutrombopag | TABLET;ORAL | 210923-001 | Jul 31, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Vancocin Italia | MULPLETA | lusutrombopag | TABLET;ORAL | 210923-001 | Jul 31, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Vancocin Italia | MULPLETA | lusutrombopag | TABLET;ORAL | 210923-001 | Jul 31, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MULPLETA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Shionogi B.V. | Mulpleo (previously Lusutrombopag Shionogi) | lusutrombopag | EMEA/H/C/004720 Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures |
Authorised | no | no | no | 2019-02-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for MULPLETA
When does loss-of-exclusivity occur for MULPLETA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Brazil
Patent: 2013007364
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 13147
Estimated Expiration: ⤷ Sign Up
China
Patent: 3228277
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 23100
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 2012043709
Estimated Expiration: ⤷ Sign Up
Patent: 57146
Estimated Expiration: ⤷ Sign Up
Patent: 94650
Estimated Expiration: ⤷ Sign Up
Patent: 14141518
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 13119966
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1849808
Estimated Expiration: ⤷ Sign Up
Patent: 130115257
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 49552
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 64008
Estimated Expiration: ⤷ Sign Up
Patent: 1216962
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering MULPLETA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 5557146 | ⤷ Sign Up | |
Spain | 2949552 | ⤷ Sign Up | |
Taiwan | I564008 | ⤷ Sign Up | |
China | 1863783 | Compounds having thrombopoietin receptor agonism | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MULPLETA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2184279 | C201930048 | Spain | ⤷ Sign Up | PRODUCT NAME: LUSUTROMBOPAG; NATIONAL AUTHORISATION NUMBER: EU/01/18/1348; DATE OF AUTHORISATION: 20190218; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/01/18/1348; DATE OF FIRST AUTHORISATION IN EEA: 20190218 |
2184279 | 132019000000090 | Italy | ⤷ Sign Up | PRODUCT NAME: LUSUTROMBOPAG(LUSUTROMBOPAG SHIONOGI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1348, 20190220 |
2184279 | 19C1043 | France | ⤷ Sign Up | PRODUCT NAME: LUSUTROMBOPAG, UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/18/1348 20190220 |
2184279 | 2019/039 | Ireland | ⤷ Sign Up | PRODUCT NAME: LUSUTROMBOPAG, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE THEREOF.; REGISTRATION NO/DATE: EU/1/18/1348 20190218 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |